NICE to reconsider lecanemab and donanemab following successful appeals The UK's National Institute for Health and Care Excellence (NICE) has confirmed it will reconsider the two anti-amyloid therapies lecanemab and donane

UK's National Institute for Health and Care Excellence (NICE) will reconsider #lecanemab and #donanemab for #Alzheimer's disease following successful appeals by the manufacturers. Our colleagues at @alzheimerssoc.bsky.social welcome the decision: www.alzheimer-europe.org/news/nice-re...

S3-Leitlinie ordnet Alzheimer-Medikamente ein Die Living Guideline Demenzen der Deutschen Gesellschaft für Neurologie (DGN) und der Deutschen Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN) ermöglicht de...

Die neu zugelassenen Wirkstoffe #Lecanemab und #Donanemab öffnen neue Perspektiven für die Behandlung von #Alzheimer Frühstadien. Die aktualisierte #S3-Leitlinie Demenzen der @dgn-ev.bsky.social und DGPPN hat die Antikörper aufgenommen. #Neurologie

Discover the incredible long-term benefits of #Donanemab, a cutting-edge treatment for early-stage #AlzheimersDisease. This innovative drug targets amyloid plaques, a key factor in Alzheimer's pathology. Clinical trials show that Donanemab not only slows cognitive decline but also enhances the quali

#UniSR Professor Massimo Filippi and his team share their real-world experience with #lecanemab and #donanemab in early #Alzheimer’s in The Lancet Regional Health – Europe, a model that can inspire #neurology worldwide. www.sciencedirect.com/science/arti...

After careful review, @swissmedic.bsky.social has officially approved #Donanemab for Alzheimer’s disease on 4 February 2026. This marks an important milestone for Alzheimer’s therapy in Switzerland.

Timely with this approval, we are hosting a webinar on #ARIA prediction, detection and management!

Alzheimer mit 57: Patientin hofft auf neues Medikament Alzheimer ist unheilbar. Ein neues Mittel macht Patienten Hoffnung. Es soll das Fortschreiten der Krankheit verlangsamen. Eine Betroffene erzählt von ihrer Erfahrung - und was sie noch alles vorhat.

Berliner Charité
#Alzheimer mit 57 Jahren
#Donanemab #Kisunla #Demenz
www.badische-zeitung.de/alzheimer-mi...

(2/2) #Trump **pure speculation continues**
#Donanemab is a treatment for early #Alzheimers and mild cognitive decline. One of the common major side effects is an MRI finding called #ARIA (amyloid related imaging abnormalities) of cerebral edema and microhemorrhages.
Serial MRIs are recommended.

(1/2) In his rambling speech yesterday, #Trump said that he aced 3 cognitive tests in front of a lot of doctors, the 3rd being just recently. He also has had at least one MRI.
**pure speculation follows**
One reason for serial MRI's and cognitive tests could be to monitor treatment with #donanemab.

¿Por qué el Alzheimer borra las caras que más queremos? Investigación de UVA vincula el olvido de personas en Alzheimer a redes neurales dañadas y apunta a fármacos para proteger la memoria social. La pérdida de reconocimiento de familiares y amigos tiene,...

¿Por qué el Alzheimer borra las caras que más queremos? #Alzheimer #Neurociencia #MemoriaSocial #Hipocampo #UVA #Investigación #Salud #España #Farmacología #Lecanemab #Donanemab #PNN #Ciencia #18denoviembre #felizmartes

donporque.com/alzheimer-bo...

China NMPA Approves Donanemab Injection for Marketing

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#Donanemab #EliLilly #AlzheimersDisease #NMPA #DrugApproval #MonoclonalAntibody #Neuroscience #ChinaPharma

Kisunla: Neues Alzheimer-Medikament in Deutschland verfügbar Erst seit wenigen Wochen ist das Lecanemab-haltige Alzheimer-Medikament Leqembi® von Biogen auf dem deutschen Markt, da bekommt es schon Konkurrenz. Do...

Erst seit wenigen Wochen ist das Lecanemab-haltige #Alzheimer Medikament Leqembi® von Biogen auf dem deutschen Markt, da bekommt es schon Konkurrenz. #Donanemab (Kisunla®, Lilly Pharma) hat das identische Anwendungsgebiet.

Eli Lilly Secures Approval for Kisunla, A Breakthrough in Alzheimer's Treatment in Europe Eli Lilly's Kisunla (donanemab) gains European Commission authorization for early-stage Alzheimer's, presenting a promising treatment option.

Eli Lilly Secures Approval for Kisunla, A Breakthrough in Alzheimer's Treatment in Europe #None #Alzheimer's #Kisunla #Donanemab

Alzheimer, ok Ue a nuovo farmaco per trattare fasi iniziali malattia (Adnkronos) - La Commissione europea ha concesso l'autorizzazione all'immissione in commercio nell'Ue per l'anticorpo monoclonale donanemab (Kisunla*), medicinale per le fasi iniziali della malattia di Alzheimer. Ne dà notizia la direz...

Alzheimer, ok Ue a nuovo farmaco per trattare fasi iniziali malattia ... LEGGI TUTTO #Alzheimer #Farmaci #Salute #RicercaMedica #Donanemab

Christian Haass @dzne.science berichtet von den heute verfügbaren Antikörpertherapien #Lecanemab / #Leqembi, #Donanemab / #Kisunla und #Aducunumab / #Aduhelm, die von Beginn an mithilfe von #Tierversuche n entwickelt wurden, und wie neue Technologien die Forschung seines Teams heute verändern.

In #Alzheimers news: “4 years on #lecanemab, the benefit tripled” … “3 years on #donanemab, the benefit doubled”, as summed by @Alzforum from #AAIC25 reported data. How the graphical illusion hides the acceleration of cognitive decline (9-part thread).
www.alzforum.org/news/confere...

“Where Did I Leave My Brain?” – The Jab That Might Actually Stop Alzheimer’s in Its Tracks! Forget overpriced supplements and turmeric yoga. Scientists may finally have a treatment that clears the fog; and no it’s not sold by Chad on Instagram!

Forget overpriced supplements and turmeric yoga. Scientists may finally have a treatment that clears the fog... and no, it’s not sold by Barry on Instagram!
.
#column #dementia #alzheimer #alzheimers #scientists #trontinemab #brain #donanemab #writer
.
www.dailydoseofdisbelief.com/where-did-i-...

Farmaci, ok Ema a donanemab, neurologi: "Svolta in lotta all'Alzheimer" (Adnkronos) - "Siamo di fronte a un momento di svolta: anche in Europa viene riconosciuta e autorizzata una ulteriore terapia in grado di modificare il decorso della malattia di Alzheimer, rallentando la progressione clinica nei pazient...

TI POTREBBE INTERESSARE: Farmaci, ok Ema a donanemab, neurologi: "Svolta in lotta all'Alzheimer" ... LEGGI TUTTO #Alzheimer #donanemab #terapia #neurologia #salute

La @ema.europa.eu ha aprobado la autorización de #donanemab (#Kisunla) en Europa, un nuevo fármaco de Eli Lilly para ralentizar el #Alzheimer en fases iniciales

Un gran avance para que el Alzheimer un día sea historia. Más info 👉 https://tinyurl.com/363c6fyd

#MakingAlzheimersHistory

Farmaci, ok Ema a donanemab, neurologi: "Svolta in lotta all'Alzheimer" (Adnkronos) - "Siamo di fronte a un momento di svolta: anche in Europa viene riconosciuta e autorizzata una ulteriore terapia in grado di modificare il decorso della malattia di Alzheimer, rallentando la progressione clinica nei pazient...

È ACCADUTO IERI: Farmaci, ok Ema a donanemab, neurologi: "Svolta in lotta all'Alzheimer" ... LEGGI TUTTO #Alzheimer #Donanemab #Ema #Neurochirurgia #Salute

Farmaci, ok Ema a donanemab, neurologi: "Svolta in lotta all'Alzheimer" (Adnkronos) - "Siamo di fronte a un momento di svolta: anche in Europa viene riconosciuta e autorizzata una ulteriore terapia in grado di modificare il decorso della malattia di Alzheimer, rallentando la progressione clinica nei pazient...

Farmaci, ok Ema a donanemab, neurologi: "Svolta in lotta all'Alzheimer" ... LEGGI TUTTO #Alzheimer #Donanemab #Ema #Neurologi #Salute

Kisunla | European Medicines Agency (EMA)

📢 Ayer la #EMA (agencia europea del medicamento) ha aprobado #donanemab para tratamiento del #Alzheimer .
2° terapia #antiamiloide que obtiene la aprobación.
Buenas noticias sin duda, pero con cautela: no es para todos y no Cita, pero puede mejorar.

www.ema.europa.eu/en/medicines...

Kisunla | European Medicines Agency (EMA)

Europar Botika agentziak (#EMA) azkenik baiezkoa eman dio #Donanemab (#Kinsula) botikaren erabilerari.
Hortaz 2 dira iada #Alzheimer -aren gaitzarentzat Euroan onartutako amiloidearen aurkako botikak. Ez dira gaixo guztientzat, baina aurrera pausu dira
www.ema.europa.eu/en/medicines...

EMA approves marketing authorization for donanemab for early-stage alzheimer’s treatment The drug was approved following a review of new data submitted by the pharmaceutical company after an initial negative opinion in March of this year.

The European Medicines Agency @ema.europa.eu has recommended the approval of #donanemab, a treatment for early-stage Alzheimer’s disease.

👇 Read more here:
www.barcelonabeta.org/en/news/news...

Eli Lilly's Donanemab Gains Positive CHMP Opinion for Alzheimer's Treatment Eli Lilly's donanemab receives a favorable opinion from the EMA's CHMP for treating early symptomatic Alzheimer’s disease, paving the way for approval.

Eli Lilly's Donanemab Gains Positive CHMP Opinion for Alzheimer's Treatment #None #Alzheimer's #Eli_Lilly #Donanemab

❗TRIAL UPDATE❗

#Donanemab is being investigated in the TRAILBLAZER trials for the treatment of #Alzheimer disease.

Discover the latest data from TRAILBLAZER-ALZ 4 here 👉 buff.ly/4eRnNgr

#NeuroSky #MedSky

NICE rejects Alzheimer’s disease drugs for third time The National Institute for Health and Clinical Excellence (NICE) has again rejected the use of Alzheimer’s disease (AD) treatments donanemab (Kisunla; Eli Lilly) and lecanemab (Leqembi; Eisai). In…

#NICE has concluded that the benefits of #donanemab and #lecanemab in the treatment of #Alzheimer's disease are too small to justify their high costs to the NHS

buff.ly/2PuF1Di

Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs

#NICE #NICEFAD #NICEfinaldraftguidance #Alzheimerstreatments #NHS #donanemab #Kisunla #EliLilly #lecanemab #Leqembi #Eisai #negativedraftrecommendations #mildcognitiveimpairment #milddementia #Alzheimersdisease #NHSresources #NICEassessments #cognitiveimpairment
www.nice.org.uk/news/article...

FDA Approves Eli Lilly’s Donanemab for Early-Stage Alzheimer’s Treatment FDA approves Kisunla, offering new hope for early Alzheimer's patients with 29% slower cognitive decline.

FDA Approves Eli Lilly’s Donanemab for Early-Stage Alzheimer’s Treatment

#fda #alzheimer #donanemab #healthcare

Alzheimer's research suffers 'devastating blow' after new drug rejected by NHS The Scottish Medicines Consortium says there isn't enough evidence to prove how well donanemab treats dementia.

Better late than never: The Scottish Medicines Consortium rejected Donanemab for use on the NHS as it said there wasn’t “enough evidence of how well it works.”
#Donanemab is way too costly for the NHS for the little benefit it offers .
#Dementia

news.stv.tv/scotland/alz...

Antikörper gegen Alzheimer: Wenig Nutzen, schwere Risiken - Gute Pillen - Schlechte Pillen Für die Zulassungsbehörde fällt die Bilanz von Vorteilen und Nachteilen für Donanemab schlechter aus als für Lecanemab.

Schwellungen und Blutungen des Gehirns sind unerwünschte Wirkungen der Antikörper gegen #Alzheimer-#Demenz – und das bei eher geringem Nutzen. Dabei scheint die Bilanz für #Donanemab schlechter zu sein als bei #Lecanemab. (€)